Almirall
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
February 23, 2024Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …
Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
November 20, 2023Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
March 31, 2023Business Services Almirall, Dermatology, dermatology, lebrikizumab
BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the …
MC2 Therapeutics grants Almirall European commercial rights for psoriasis cream Wynzora
February 18, 2021Almirall, MC2 Therapeutics, psoriasis
Biopharma company Almirall and MC2 Therapeutics, a pharmaceutical company focused on therapies for autoimmune and chronic inflammatory conditions, have announced …
NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis
December 4, 2018Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis
UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …
Almirall’s Ilumetri scores EU approval in chronic plaque psoriasis
September 19, 2018Research and Development, Sales and Marketing Almirall, EADV 2018, Ilumetri, pharma, psoriasis
Hot on the heels of the European Academy of Dermatology and Venereology Congress (EADV) 2018 where psoriasis took centre stage, …
Almirall picks up Allergan’s dermatology portfolio to for $650m
August 3, 2018Medical Communications, Sales and Marketing Allergan, Almirall, dermatology, pharma
Allergan has sealed a deal to sell its dermatology portfolio, comprising five brands, to Spanish pharmaceutical firm Almirall for $650 …
EVP of Diabetes decamps from Sanofi to become Almirall CEO
August 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Almirall, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi’s Executive Vice President of Diabetes & Cardiocascular, Peter Guenter, has opted to end his 22-year-long stay at the company …
NICE recommends plaque psoriasis contender for NHS use
August 8, 2017Manufacturing and Production, Sales and Marketing Almirall, NICE< Skilarence, drugs, life sciences, medicine, pharma, pharmaceuticals, plaque psoriasis, psoriasis
The use of Almirall’s psoriasis drug Skilarence (dimethyl fumarate) on the UK’s NHS is one step closer after NICE gave …
Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million
March 17, 2016Business Services, Sales and Marketing Almirall, Grünenthal Group, merger and acquisition
Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about €50 million ,to …
Almirall to acquire Poli Group’s skin drugs
November 30, 2015Sales and Marketing Almirall, Poldi, dermatology, skin, specialty pharma
Almirall has agreed to acquire 100% of the share capital of Poli Group Holding as the Spanish pharma company continues …
Almirall presents new data on cannabinoid-based MS treatment
October 9, 2015Research and Development Almirall, multiple sclerosis
Almirall has presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, …
AstraZeneca completes respiratory deal with Almirall
November 3, 2014Research and Development, Sales and Marketing Almirall, AstraZeneca, Pfizer, deal, duaklir, merger, respiratory
AstraZeneca has finally completed its takeover of Almirall’s respiratory drug portfolio in a deal worth $875 million. As reported by …
AstraZeneca secures respiratory drugs from Almirall
July 30, 2014Research and Development, Sales and Marketing Almirall, AstraZeneca, Pfizer, Symbicort, lung drugs
AstraZeneca has paid $875 million to take control of Alimirall’s respiratory drug portfolio that includes treatments for bronchitis and emphysema. …
Almirall appoints first woman to its Board
November 21, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Almirall
Karin Louise Dorrepaal is the first woman to join Almirall’s ten-member Board of directors. Dorrepaal, who is Dutch, has extensive …
Latest content
